and provide palliative care to pediatric populations. NINR is launching this effort to increase the use of palliative care for children living with serious illness or life-limiting conditions. The Palliative Care: Conversations Matter evaluation will assess the information and materials being disseminated as part of the official campaign. Survey findings will help (1) Determine if the program is effective, relevant, and useful to health care providers who recommend and provide palliative care to pediatric populations; (2) to better understand the information needs of health care providers to inform future campaign efforts; and (3) examine how effective the campaign materials are in starting and continuing a pediatric palliative care conversation and addressing the communications needs of health care providers around this topic.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 200.

Estimated Annualized Burden Hours

<table>
<thead>
<tr>
<th>Type of respondents</th>
<th>Number of respondents</th>
<th>Frequency of response</th>
<th>Average time per response (in hours)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>150</td>
<td>2</td>
<td>20/60</td>
<td>100</td>
</tr>
<tr>
<td>Nurses</td>
<td>150</td>
<td>2</td>
<td>20/60</td>
<td>100</td>
</tr>
<tr>
<td>Total</td>
<td>300</td>
<td></td>
<td></td>
<td>200</td>
</tr>
</tbody>
</table>

* The average time for completing one of the surveys is 20 minutes; this includes reading the consent form on page 1 of the survey.

Dated: August 19, 2013.

Amanda Greene,
NINR PRA Liaison, Science Evaluation Officer, NINR, NIH.

[FR Doc. 2013–21005 Filed 8–27–13; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive Patent License: Use of Exenatide for the Treatment of Neurodegenerative Diseases

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.


DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 27, 2013 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, comments, and other materials relating to the contemplated Exclusive Patent License should be directed to: Tara L. Kirby, Ph.D., Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4426; Facsimile:...
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel Detection of Pathogen Induced Cancer.
Date: October 1, 2013.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W034, Rockville, MD 20850, (Telephone Conference Call).
Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, MD 20850, 240–276–6368, stoicaa2@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis Panel Planning for a National Center for Particle Beam Radiation Therapy Research.
Date: October 3, 2013.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 6W032, Rockville, MD 20850, (Telephone Conference Call).
Contact Person: Thomas A. Winters, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892–9750, 240–276–6386, twinters@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis Panel Informatics Technology for Cancer Research.
Date: October 22, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites-Hotel, 6711 Democracy Blvd., Bethesda, MD 20817.
Contact Person: Viatcheslav A. Soldatenkov, MD, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W254, Bethesda, MD 20892–8329, 240–276–6378, soldatenkovv@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel NCI Omnibus Grants on Cancer Genetics and Etiology.
Date: October 22–23, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites Alexandria—Old Town, 1900 Diagonal Road, Alexandria, VA 22314.
Contact Person: Marvin L. Salin, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236, Bethesda, MD 20892–8329, 240–276–6369, msalin@mail.nih.gov.
Name of Committee: National Cancer Institute Initial Review Group Subcommittee F—Institutional Training and Education.
Date: October 28–29, 2013.
Time: 7:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Arlington Capital View, 2850 South Potomac Avenue, Arlington, VA 22202.
Contact Person: Timothy C. Meeker, Ph.D., MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Bethesda, MD 20850, 240–276–6464, meekert@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis Panel Research Answers to NCI’s Provocative Questions-Group A (R01).
Date: October 31—November 1, 2013.
Time: 7:30 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.
Contact Person: Clifford W Schweinfest, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W108, Bethesda, MD 20892–9750, 240–276–6378, schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis Panel Collaborative Human Tissue Network (CHTN) (UM1).
Date: November 4–5, 2013.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room: Nov 4–6W030 & Nov 5–7W030, Rockville, MD 20850, (Telephone Conference Call).
Contact Person: Donald L Coppock, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236, Bethesda, MD 20892–8329, 240–276–6369, soldatenkovv@mail.nih.gov.